Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 6/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HTR1B | P28222 | 4/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | PTGIR | P43119 | 1/20 | 0.55 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036369 | 0.91 | HTR1D (0.60) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL2869241 | 0.83 | HTR1D (0.69) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL9393147 | 0.83 | HTR1D (0.69) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL953972 | 0.83 | RAD52 (0.82) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL34961 | 0.82 | TAAR1 (1.00) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL10846015 | 0.82 | TAAR1 (0.72) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL5053858 | 0.81 | TAAR1 (1.00) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL9614505 | 0.81 | TAAR1 (1.00) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL34869 | 0.81 | TAAR1 (1.00) | HTR1DTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL5326165 | 0.79 | TAAR1 (0.68) | HTR1DTAAR1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | claimed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, LTB4R | HTR1D 347/4885TAAR1 109/4885ADRA2A 179/4885 |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | HTR1D 231/4885TAAR1 351/4885ADRA2A 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.